Market closedNon-fractional
SCYNEXIS/SCYX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About SCYNEXIS
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Ticker
SCYX
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Jersey City, United States
Employees
29
Website
www.scynexis.com
SCYNEXIS Metrics
BasicAdvanced
$71M
Market cap
0.89
P/E ratio
$2.09
EPS
1.49
Beta
-
Dividend rate
Price and volume
Market cap
$71M
Beta
1.49
Financial strength
Current ratio
3.718
Quick ratio
3.646
Long term debt to equity
3.356
Total debt to equity
20.557
Interest coverage (TTM)
14.69%
Management effectiveness
Return on assets (TTM)
48.95%
Return on equity (TTM)
458.59%
Valuation
Price to earnings (TTM)
0.894
Price to revenue (TTM)
0.639
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
1.195
Growth
Revenue change (TTM)
2,436.75%
Earnings per share change (TTM)
-206.72%
3-year revenue growth
126.70%
3-year earnings per share growth
-17.13%
What the Analysts think about SCYNEXIS
Analyst Ratings
Majority rating from 5 analysts.
SCYNEXIS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.3M
-77.19%
Net income
$400K
-102.05%
Profit margin
30.76%
-108.99%
SCYNEXIS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.46
-$0.04
-$0.39
$0.01
-
Expected
$1.55
-$0.15
-$0.20
-$0.20
-$0.16
Surprise
58.91%
-72.60%
95.00%
-105.06%
-
SCYNEXIS News
AllArticlesVideos
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
GlobeNewsWire·2 months ago
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SCYNEXIS stock?
SCYNEXIS (SCYX) has a market cap of $71M as of July 06, 2024.
What is the P/E ratio for SCYNEXIS stock?
The price to earnings (P/E) ratio for SCYNEXIS (SCYX) stock is 0.89 as of July 06, 2024.
Does SCYNEXIS stock pay dividends?
No, SCYNEXIS (SCYX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next SCYNEXIS dividend payment date?
SCYNEXIS (SCYX) stock does not pay dividends to its shareholders.
What is the beta indicator for SCYNEXIS?
SCYNEXIS (SCYX) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell SCYNEXIS stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.